thanks
@Shellbell. I think the CEO is being very bullish in her language as well:
- “really exciting” AML trial for our CORE NK Asset
- “really can’t wait to share the results” for the first cohort of CDH17 CART patients soon
- suggested that the data for the CORE NK trial will be presented at the ASH conference later this year.
this is very strong language indeed. Company has not been this bullish before from memory.
So my confidence levels that this company will unveil some incredible data for at least two of its assets in the near term are at an all time high.
watch this space!
(20min delay)